ladiratuzumab vedotin + trastuzumab

This is a **combination therapy of ladiratuzumab vedotin and trastuzumab**, both monoclonal antibody-based drugs. Ladiratuzumab vedotin is an antibody-drug conjugate (ADC) targeting the zinc transporter **LIV-1** (SLC39A6) and delivers the potent microtubule-disrupting agent **monomethyl auristatin E (MMAE)** via a cleavable linker. Its mechanism involves binding to LIV-1, internalization, proteolytic release of MMAE, and subsequent disruption of tumor microtubules, as well as potential immune activation mechanisms. Trastuzumab is a monoclonal antibody targeting **human epidermal growth factor receptor 2 (HER2, ERBB2)**. It inhibits HER2 signaling and mediates antibody-dependent cellular cytotoxicity (ADCC), leading to cell death in HER2-overexpressing tumors. This combination is under investigation for breast cancer (notably triple-negative and/or HER2-expressing subtypes), focusing on mechanisms targeting both LIV-1 and HER2 pathways[1][3][5][4][6].

Brand names

HerwendaZ ErcepacZercepac

Other names

ladiratuzumab vedotintrastuzumab